Tirzepatide, a GLP-1 receptor agonist, is currently being evaluated for its efficacy in reducing alcohol consumption and improving cardiometabolic health in adults with Alcohol Use Disorder (AUD) and obesity. The trial is sponsored by the University of Southern California and is actively recruiting participants. If successful, this indication could expand Tirzepatide's market potential beyond diabetes and obesity, tapping into the significant unmet need for effective treatments for AUD. The competitive landscape includes existing pharmacotherapies for AUD, such as naltrexone and acamprosate, but Tirzepatide's novel mechanism may offer a differentiated profile. Diligence should focus on the trial's design, recruitment pace, and any emerging safety or efficacy signals that could impact market entry timelines and commercial viability.